A Phase 3 interventional study of Niraparib and Placebo in Neoplasms, Breast, sponsored by GlaxoSmithKline. Active, not recruiting at 198 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 355th largest by enrollment of the 605 interventional ones that give a count, is one of 50 that started in 2021, is one of 27 in phase 3, reaches primary completion later than 21 of the 263 other live ones, and was the 421st registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 18–75 · Women only
Medical University of South Carolina · Sites in United States
Ages 18+
Stephen Shiao · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 300 · Phase 3 29
First in 2001; this study’s year is marked. 50 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 52 across the 605 interventional studies, 90 across the 38 observational. Of the 338 that completed or were terminated, 179 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
319 of 645 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 3 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
93 of the studies in Triple Negative Breast Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT05633654Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | 2027-06 |
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06545331ExelixisStudy of XB010 in Subjects With Solid Tumors | 2026-11-23 |
| NCT02276443M.D. Anderson Cancer CenterMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | 2026-11-30 |
Add all 93 to your calendar (.ics) → With an account.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor [HR] status, including HR positive [+] and TNBC) or tumor BRCA wild type (tBRCAwt) TNBC with molecular disease based on the presence of circulating tumor Deoxyribonucleic acid (ctDNA) following surgery or completion of adjuvant therapy.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
This study's enrollment of 40 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Browse Triple Negative Breast Neoplasms studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will receive either Niraparib or Placebo.
Drug: Niraparib · Drug: Placebo
Eligible participants will receive either Niraparib or Placebo.
Drug: Niraparib · Drug: Placebo
Niraparib will be administered.
Matching placebo will be administered
Number of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AESI is any AE (serious or nonserious) that is of scientific and medical concern specific to niraparib for which ongoing monitoring and rapid communication by the Investigator to the Sponsor is warranted. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 125 weeks
Number of Participants With TEAEs Leading to Death
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state.Number of participants with TEAEs leading to death were reported.
Time frame: Up to approximately 125 weeks
Number of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with TEAEs leading to dose modifications (reduction and interruption/delay) and permanent discontinuation of study treatment were reported.
Time frame: Up to approximately 125 weeks
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
Number of participants with ECOG Performance Status was reported and was measured on 6-point grade scale 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead. Data is presented as baseline grade, best case on-therapy, and worst-case on-therapy for the available participants.
Time frame: Up to approximately 125 weeks
Number of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline
Blood samples were collected for the analysis of hematology parameters. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.
Time frame: Up to approximately 125 weeks
Number of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low, changes to normal or no changes from Baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.
Time frame: Up to approximately 125 weeks
Number of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline
The abnormal vital sign ranges are: Pulse Rate (PR): Low \[\<60 beats per minute (bpm)\], Normal (60 bpm to 100 bpm), High (\>100 bpm); Temperature: Low (\<35 degree Celsius (°C)), Normal (35 C and 38 C), High (\>38 C); Systolic Blood Pressure (SBP): Low (\<90 millimeter of mercury (mmHg)), Normal (\>90 mmHg to \<120 mmHg), High (\>120 mmHg); Diastolic Blood Pressure (DBP): Low (\<60 mmHg), Normal (60 mmHg to 79 mmHg), High (\>80 mmHg). Participants were counted in the maximum worst case increase category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category.
Time frame: Up to approximately 125 weeks
Number of Participants With Use of Concomitant Medications
Number of participants who used concomitant medications is presented.
Time frame: Up to approximately 125 weeks
| Milestone | Niraparib | Placebo |
|---|---|---|
| Started | 18 | 22 |
| Completed | 4 | 6 |
| Not completed | 14 | 16 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Ongoing for pact | 3 | 2 |
| Withdrew: Other | 7 | 11 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AESI is any AE (serious or nonserious) that is of scientific and medical concern specific to niraparib for which ongoing monitoring and rapid communication by the Investigator to the Sponsor is warranted. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Niraparib | Placebo |
|---|---|---|
| TEAEs | 18 | 17 |
| SAEs | 5 | 1 |
| AESIs | 0 | 0 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state.Number of participants with TEAEs leading to death were reported.
| Participants | Niraparib | Placebo |
|---|---|---|
| Number of Participants With TEAEs Leading to Death | 0 | 0 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with TEAEs leading to dose modifications (reduction and interruption/delay) and permanent discontinuation of study treatment were reported.
| Participants | Niraparib | Placebo |
|---|---|---|
| Dose reduction | 10 | 0 |
| Dose interruption/delay | 11 | 1 |
| Permanent discontinuation of study treatment | 0 | 0 |
Number of participants with ECOG Performance Status was reported and was measured on 6-point grade scale 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead. Data is presented as baseline grade, best case on-therapy, and worst-case on-therapy for the available participants.
| Participants | Niraparib | Placebo |
|---|---|---|
| Baseline, Grade 0 | 16 | 16 |
| Baseline, Grade 1 | 2 | 6 |
| Worst Case On-therapy, Grade 0 | 7 | 9 |
| Worst Case On-therapy, Grade 1 | 9 | 11 |
| Worst Case On-therapy, Grade 2 | 2 | 0 |
| Worst Case On-therapy, Grade 3 | 0 | 1 |
| Best Case On-therapy, Grade 0 | 17 | 17 |
| Best Case On-therapy, Grade 1 | 1 | 4 |
Blood samples were collected for the analysis of hematology parameters. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.
| Participants | Niraparib | Placebo |
|---|---|---|
| Basophils, To Low | 3 | 1 |
| Basophils, To Normal or No Change | 12 | 19 |
| Basophils, To High | 1 | 0 |
| Eosinophils, To Low | 4 | 3 |
| Eosinophils, To Normal or No Change | 12 | 15 |
| Eosinophils, To High | 0 | 2 |
| Erythrocyte Mean Corpuscular Volume (MCV), To Low | 1 | 1 |
| MCV, To Normal or No Change | 9 | 21 |
| MCV, To High | 9 | 0 |
| Hematocrit, To Low | 10 | 6 |
| Hematocrit, To Normal or No Change | 8 | 15 |
| Hematocrit, To High | 1 | 1 |
| Hemoglobin, To Low | 9 | 6 |
| Hemoglobin, To Normal or No Change | 9 | 16 |
| Hemoglobin, To High | 0 | 0 |
| Leukocytes, To Low | 13 | 2 |
| Leukocytes, To Normal or No Change | 3 | 19 |
| Leukocytes, To High | 4 | 1 |
| Lymphocytes, To Low | 9 | 1 |
| Lymphocytes, To Normal or No Change | 9 | 21 |
| Lymphocytes, To High | 0 | 0 |
| Monocytes, To Low | 5 | 1 |
| Monocytes, To Normal or No Change | 10 | 17 |
| Monocytes, To High | 1 | 2 |
| Neutrophils, To Low | 9 | 6 |
| Neutrophils, To Normal or No Change | 8 | 14 |
| Neutrophils, To High | 3 | 2 |
| Platelets, To Low | 8 | 0 |
| Platelets, To Normal or No Change | 7 | 21 |
| Platelets, To High | 4 | 1 |
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low, changes to normal or no changes from Baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.
| Participants | Niraparib | Placebo |
|---|---|---|
| Alanine aminotransferase (ALT), To Low | 0 | 1 |
| ALT, To Normal or No Change | 12 | 15 |
| ALT, To High | 6 | 5 |
| Albumin, To Low | 1 | 3 |
| Albumin, To Normal or No Change | 15 | 18 |
| Albumin, To High | 2 | 0 |
| Alkaline phosphatase (AP), To Low | 1 | 0 |
| AP, To Normal or No Change | 13 | 16 |
| AP, To High | 4 | 4 |
| Amylase, To Low | 0 | 0 |
| Amylase, To Normal or No Change | 8 | 7 |
| Amylase, To High | 0 | 0 |
| Aspartate aminotransferase (AST), To Low | 0 | 0 |
| AST, To Normal or No Change | 12 | 18 |
| AST, To High | 6 | 3 |
| Bicarbonate, To Low | 2 | 1 |
| Bicarbonate, To Normal or No Change | 5 | 9 |
| Bicarbonate, To High | 6 | 3 |
| Bilirubin, To Low | 2 | 3 |
| Bilirubin, To Normal or No Change | 14 | 18 |
| Bilirubin, To High | 2 | 0 |
| Calcium, To Low | 3 | 0 |
| Calcium, To Normal or No Change | 12 | 18 |
| Calcium, To High | 3 | 3 |
| Carbon Dioxide, To Low | 0 | 0 |
| Carbon Dioxide, To Normal or No Change | 4 | 4 |
| Carbon Dioxide, To High | 0 | 0 |
| Chloride, To Low | 4 | 3 |
| Chloride, To Normal or No Change | 11 | 14 |
| Chloride, To High | 3 | 4 |
| Creatinine, To Low | 1 | 1 |
| Creatinine, To Normal or No Change | 11 | 17 |
| Creatinine, To High | 6 | 2 |
| Direct Bilirubin, To Low | 1 | 0 |
| Direct Bilirubin, To Normal or No Change | 12 | 13 |
| Direct Bilirubin, To High | 2 | 2 |
| Glucose, To Low | 1 | 2 |
| Glucose, To Normal or No Change | 11 | 13 |
| Glucose, To High | 7 | 6 |
| Lipase, To Low | 0 | 0 |
| Lipase, To Normal or No Change | 3 | 4 |
| Lipase, To High | 0 | 0 |
| Magnesium, To Low | 1 | 1 |
| Magnesium, To Normal or No Change | 8 | 7 |
| Magnesium, To High | 0 | 0 |
| Phosphate, To Low | 0 | 0 |
| Phosphate, To Normal or No Change | 5 | 10 |
| Phosphate, To High | 2 | 0 |
| Potassium, To Low | 2 | 2 |
| Potassium, To Normal or No Change | 13 | 16 |
| Potassium, To High | 3 | 3 |
| Protein, To Low | 6 | 2 |
| Protein, To Normal or No Change | 11 | 17 |
| Protein, To High | 1 | 1 |
| Sodium, To Low | 3 | 1 |
| Sodium, To Normal or No Change | 14 | 19 |
| Sodium, To High | 1 | 1 |
| Urate, To Low | 3 | 1 |
| Urate, To Normal or No Change | 2 | 6 |
| Urate, To High | 1 | 0 |
| Urea, To Low | 0 | 1 |
| Urea, To Normal or No Change | 10 | 13 |
| Urea, To High | 5 | 1 |
| Urea Nitrogen, To Low | 0 | 1 |
| Urea Nitrogen, To Normal or No Change | 2 | 3 |
| Urea Nitrogen, To High | 0 | 1 |
The abnormal vital sign ranges are: Pulse Rate (PR): Low \[\<60 beats per minute (bpm)\], Normal (60 bpm to 100 bpm), High (\>100 bpm); Temperature: Low (\<35 degree Celsius (°C)), Normal (35 C and 38 C), High (\>38 C); Systolic Blood Pressure (SBP): Low (\<90 millimeter of mercury (mmHg)), Normal (\>90 mmHg to \<120 mmHg), High (\>120 mmHg); Diastolic Blood Pressure (DBP): Low (\<60 mmHg), Normal (60 mmHg to 79 mmHg), High (\>80 mmHg). Participants were counted in the maximum worst case increase category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category.
| Participants | Niraparib | Placebo |
|---|---|---|
| DBP, To Low | 0 | 0 |
| DBP, To within Range or No Change | 13 | 22 |
| DBP, To High | 5 | 0 |
| PR, To Low | 1 | 4 |
| PR, To within Range or No Change | 9 | 16 |
| PR, To High | 8 | 2 |
| SBP, To Low | 0 | 0 |
| SBP, To within Range or No Change | 12 | 21 |
| SBP, To High | 6 | 1 |
| Temperature, To Low | 0 | 0 |
| Temperature, To within Range or No Change | 18 | 21 |
| Temperature, To High | 0 | 0 |
Number of participants who used concomitant medications is presented.
| Participants | Niraparib | Placebo |
|---|---|---|
| Number of Participants With Use of Concomitant Medications | 18 | 18 |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected approximately 125 weeks. The results presented are based on data cut-off date 28 June 2024.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niraparib | 0/18 (0%) | 5/18 (27.8%) | 18/18 (100%) |
| Placebo | 3/22 (13.6%) | 1/22 (4.5%) | 17/22 (77.3%) |
| Event | Niraparib | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/18 | 0/22 |
| Subendocardial ischaemiaCardiac disorders | 1/18 | 0/22 |
| Macular holeEye disorders | 1/18 | 0/22 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/18 | 0/22 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/18 | 0/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/18 | 1/22 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/18 | 1/22 |
| Event | Niraparib | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 8/18 | 3/22 |
| FatigueGeneral disorders | 7/18 | 7/22 |
| AnaemiaBlood and lymphatic system disorders | 6/18 | 2/22 |
| HypertensionVascular disorders | 6/18 | 0/22 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/18 | 1/22 |
| DiarrhoeaGastrointestinal disorders | 2/18 | 6/22 |
| NauseaGastrointestinal disorders | 4/18 | 6/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/18 | 5/22 |
| HeadacheNervous system disorders | 4/18 | 5/22 |
| AstheniaGeneral disorders | 3/18 | 4/22 |
| Age, Continuous(YEARS) | Niraparib | Placebo | Total |
|---|---|---|---|
| Mean | 58.1 ± 10.03 | 54.3 ± 14.22 | 56.0 ± 12.51 |
| Sex: Female, Male(Participants) | Niraparib | Placebo | Total |
|---|---|---|---|
| Female | 18 | 22 | 40 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Niraparib | Placebo | Total |
|---|---|---|---|
| White | 12 | 18 | 30 |
| Unknown | 0 | 1 | 1 |
| All other races | 6 | 3 | 9 |
Showing the first 100 of 198 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Jun 2021 to primary completion in Jun 2024, 36 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's 36 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niraparib
Triple Negative Breast Neoplasms →